Which has better earnings and valuation, PROF or BVS?

Bioventus has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profound Medical $18.81M 13.23 -$42.57M -$1.24 N/A Bioventus $568.09M 1.77 $22.73M $0.41 29.41

Does the media favor PROF or BVS?

In the previous week, Profound Medical had 3 more articles in the media than Bioventus. MarketBeat recorded 6 mentions for Profound Medical and 3 mentions for Bioventus. Bioventus' average media sentiment score of 0.83 beat Profound Medical's score of 0.49 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Profound Medical 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bioventus 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PROF or AVR?

In the previous week, Profound Medical had 4 more articles in the media than Anteris Technologies Global. MarketBeat recorded 6 mentions for Profound Medical and 2 mentions for Anteris Technologies Global. Profound Medical's average media sentiment score of 0.49 beat Anteris Technologies Global's score of 0.40 indicating that Profound Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Profound Medical 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anteris Technologies Global 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, INMD or PROF?

InMode has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMode $374.64M 2.37 $93.83M $1.36 11.38 Profound Medical $18.81M 13.23 -$42.57M -$1.24 N/A

Is INMD or PROF more profitable?

InMode has a net margin of 23.27% compared to Profound Medical's net margin of -206.76%. InMode's return on equity of 13.47% beat Profound Medical's return on equity. Company Net Margins Return on Equity Return on Assets InMode 23.27% 13.47% 11.95% Profound Medical -206.76% -78.88% -64.06%

Does the media prefer INMD or PROF?

In the previous week, InMode had 1 more articles in the media than Profound Medical. MarketBeat recorded 7 mentions for InMode and 6 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.49 beat InMode's score of 0.11 indicating that Profound Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Profound Medical 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BBNX or PROF?

In the previous week, Profound Medical had 5 more articles in the media than Beta Bionics. MarketBeat recorded 6 mentions for Profound Medical and 1 mentions for Beta Bionics. Profound Medical's average media sentiment score of 0.49 beat Beta Bionics' score of 0.00 indicating that Profound Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Profound Medical 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, SIBN or PROF?

SiBone has higher revenue and earnings than Profound Medical. SiBone is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 3.84 -$18.90M -$0.39 N/A Profound Medical $18.81M 13.23 -$42.57M -$1.24 N/A

Is SIBN or PROF more profitable?

SiBone has a net margin of -8.10% compared to Profound Medical's net margin of -206.76%. SiBone's return on equity of -9.56% beat Profound Medical's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% Profound Medical -206.76% -78.88% -64.06%

Does the media prefer SIBN or PROF?

In the previous week, Profound Medical had 2 more articles in the media than SiBone. MarketBeat recorded 6 mentions for Profound Medical and 4 mentions for SiBone. Profound Medical's average media sentiment score of 0.49 beat SiBone's score of 0.26 indicating that Profound Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Profound Medical 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Profound Medical (PROF) Competitors

$6.85 +0.07 (+1.03%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$6.82 -0.03 (-0.44%)

As of 07/17/2026 04:10 PM Eastern

Compare

PROF vs. BVS, AVR, INMD, BBNX, and SIBN

Should you buy Profound Medical stock or one of its competitors? MarketBeat compares Profound Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Profound Medical include Bioventus (BVS), Anteris Technologies Global (AVR), InMode (INMD), Beta Bionics (BBNX), and SiBone (SIBN). These companies are all part of the "medical equipment" industry.

How does Profound Medical compare to Bioventus?

Profound Medical (NASDAQ:PROF) and Bioventus (NASDAQ:BVS) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Profound Medical has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, Bioventus has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

47.9% of Profound Medical shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 1.5% of Profound Medical shares are held by insiders. Comparatively, 33.5% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Bioventus has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$18.81M	13.23	-$42.57M	-$1.24	N/A
Bioventus	$568.09M	1.77	$22.73M	$0.41	29.41

Profound Medical currently has a consensus price target of $12.00, indicating a potential upside of 75.18%. Bioventus has a consensus price target of $14.75, indicating a potential upside of 22.31%. Given Profound Medical's higher probable upside, analysts plainly believe Profound Medical is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Bioventus has a net margin of 4.94% compared to Profound Medical's net margin of -206.76%. Bioventus' return on equity of 29.97% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-206.76%	-78.88%	-64.06%
Bioventus	4.94%	29.97%	9.52%

In the previous week, Profound Medical had 3 more articles in the media than Bioventus. MarketBeat recorded 6 mentions for Profound Medical and 3 mentions for Bioventus. Bioventus' average media sentiment score of 0.83 beat Profound Medical's score of 0.49 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profound Medical	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bioventus	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bioventus beats Profound Medical on 13 of the 17 factors compared between the two stocks.

How does Profound Medical compare to Anteris Technologies Global?

Profound Medical (NASDAQ:PROF) and Anteris Technologies Global (NASDAQ:AVR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Profound Medical has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market. Comparatively, Anteris Technologies Global has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market.

Profound Medical has a net margin of -206.76% compared to Anteris Technologies Global's net margin of -5,148.78%. Profound Medical's return on equity of -78.88% beat Anteris Technologies Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-206.76%	-78.88%	-64.06%
Anteris Technologies Global	-5,148.78%	-124.76%	-101.21%

In the previous week, Profound Medical had 4 more articles in the media than Anteris Technologies Global. MarketBeat recorded 6 mentions for Profound Medical and 2 mentions for Anteris Technologies Global. Profound Medical's average media sentiment score of 0.49 beat Anteris Technologies Global's score of 0.40 indicating that Profound Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profound Medical	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anteris Technologies Global	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Profound Medical currently has a consensus price target of $12.00, indicating a potential upside of 75.18%. Anteris Technologies Global has a consensus price target of $16.00, indicating a potential upside of 89.35%. Given Anteris Technologies Global's stronger consensus rating and higher possible upside, analysts clearly believe Anteris Technologies Global is more favorable than Profound Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

47.9% of Profound Medical shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by insiders. Comparatively, 4.5% of Anteris Technologies Global shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profound Medical has higher revenue and earnings than Anteris Technologies Global. Profound Medical is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$18.81M	13.23	-$42.57M	-$1.24	N/A
Anteris Technologies Global	$1.91M	430.64	-$94.14M	-$2.23	N/A

Summary

Profound Medical beats Anteris Technologies Global on 9 of the 16 factors compared between the two stocks.

How does Profound Medical compare to InMode?

InMode (NASDAQ:INMD) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

InMode has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

InMode presently has a consensus price target of $16.00, indicating a potential upside of 3.43%. Profound Medical has a consensus price target of $12.00, indicating a potential upside of 75.18%. Given Profound Medical's higher possible upside, analysts plainly believe Profound Medical is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

InMode has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$374.64M	2.37	$93.83M	$1.36	11.38
Profound Medical	$18.81M	13.23	-$42.57M	-$1.24	N/A

68.0% of InMode shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 6.9% of InMode shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, InMode had 1 more articles in the media than Profound Medical. MarketBeat recorded 7 mentions for InMode and 6 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.49 beat InMode's score of 0.11 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Profound Medical	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InMode has a net margin of 23.27% compared to Profound Medical's net margin of -206.76%. InMode's return on equity of 13.47% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	23.27%	13.47%	11.95%
Profound Medical	-206.76%	-78.88%	-64.06%

Summary

InMode beats Profound Medical on 11 of the 14 factors compared between the two stocks.

How does Profound Medical compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Beta Bionics has a beta of 3.04, suggesting that its stock price is 204% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

47.9% of Profound Medical shares are held by institutional investors. 5.3% of Beta Bionics shares are held by company insiders. Comparatively, 1.5% of Profound Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Profound Medical had 5 more articles in the media than Beta Bionics. MarketBeat recorded 6 mentions for Profound Medical and 1 mentions for Beta Bionics. Profound Medical's average media sentiment score of 0.49 beat Beta Bionics' score of 0.00 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Profound Medical	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Beta Bionics has a net margin of -60.27% compared to Profound Medical's net margin of -206.76%. Beta Bionics' return on equity of -23.00% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Profound Medical	-206.76%	-78.88%	-64.06%

Profound Medical has lower revenue, but higher earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$110.24M	6.99	-$73.20M	-$1.51	N/A
Profound Medical	$18.81M	13.23	-$42.57M	-$1.24	N/A

Beta Bionics currently has a consensus price target of $20.30, indicating a potential upside of 17.41%. Profound Medical has a consensus price target of $12.00, indicating a potential upside of 75.18%. Given Profound Medical's higher probable upside, analysts clearly believe Profound Medical is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Beta Bionics beats Profound Medical on 9 of the 17 factors compared between the two stocks.

How does Profound Medical compare to SiBone?

SiBone (NASDAQ:SIBN) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

98.1% of SiBone shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 4.0% of SiBone shares are held by insiders. Comparatively, 1.5% of Profound Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Profound Medical had 2 more articles in the media than SiBone. MarketBeat recorded 6 mentions for Profound Medical and 4 mentions for SiBone. Profound Medical's average media sentiment score of 0.49 beat SiBone's score of 0.26 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Profound Medical	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SiBone has a net margin of -8.10% compared to Profound Medical's net margin of -206.76%. SiBone's return on equity of -9.56% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Profound Medical	-206.76%	-78.88%	-64.06%

SiBone has higher revenue and earnings than Profound Medical. SiBone is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.84	-$18.90M	-$0.39	N/A
Profound Medical	$18.81M	13.23	-$42.57M	-$1.24	N/A

SiBone has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

SiBone currently has a consensus target price of $23.50, suggesting a potential upside of 35.21%. Profound Medical has a consensus target price of $12.00, suggesting a potential upside of 75.18%. Given Profound Medical's higher possible upside, analysts plainly believe Profound Medical is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

SiBone beats Profound Medical on 10 of the 16 factors compared between the two stocks.

Get Profound Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PROF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PROF vs. The Competition

Export

Metric	Profound Medical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$248.94M	$3.04B	$6.86B	$12.28B
Dividend Yield	N/A	2.06%	2.67%	9.34%
P/E Ratio	-5.52	20.17	27.25	23.92
Price / Sales	13.23	494.99	517.85	89.25
Price / Cash	N/A	57.26	52.99	60.41
Price / Book	3.74	4.26	10.69	6.18
Net Income	-$42.57M	$65.46M	$3.59B	$332.29M
7 Day Performance	-2.70%	-3.20%	-2.20%	-2.05%
1 Month Performance	-0.29%	0.70%	1.63%	-2.18%
1 Year Performance	21.45%	19.10%	25.64%	17.67%

Profound Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PROF Profound Medical	1.6495 of 5 stars	$6.85 +1.0%	$12.00 +75.2%	+21.5%	$248.94M	$18.81M	N/A	150	News Coverage Analyst Downgrade
BVS Bioventus	4.2869 of 5 stars	$11.56 -4.2%	$14.75 +27.6%	+92.7%	$965.72M	$568.09M	28.20	1,200
AVR Anteris Technologies Global	2.883 of 5 stars	$8.95 -4.4%	$16.00 +78.8%	+177.0%	$871.19M	$1.91M	N/A	138
INMD InMode	1.7411 of 5 stars	$14.92 -1.5%	$16.00 +7.2%	+11.3%	$857.60M	$370.49M	10.97	480	News Coverage Upcoming Earnings
BBNX Beta Bionics	1.7072 of 5 stars	$16.86 -0.5%	$20.10 +19.2%	+27.2%	$751.28M	$100.25M	N/A	294	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PROF) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Profound Medical (PROF) Competitors

PROF vs. BVS, AVR, INMD, BBNX, and SIBN

How does Profound Medical compare to Bioventus?

Summary

How does Profound Medical compare to Anteris Technologies Global?

Summary

How does Profound Medical compare to InMode?

Summary

How does Profound Medical compare to Beta Bionics?

Summary

How does Profound Medical compare to SiBone?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROF vs. The Competition

Profound Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Profound Medical (PROF) Competitors

PROF vs. BVS, AVR, INMD, BBNX, and SIBN

How does Profound Medical compare to Bioventus?

Which has more volatility & risk, PROF or BVS?

Do institutionals & insiders believe in PROF or BVS?

Which has better earnings and valuation, PROF or BVS?

Do analysts prefer PROF or BVS?

Is PROF or BVS more profitable?

Does the media favor PROF or BVS?

Summary

How does Profound Medical compare to Anteris Technologies Global?

Which has more volatility & risk, PROF or AVR?

Is PROF or AVR more profitable?

Does the media favor PROF or AVR?

Do analysts recommend PROF or AVR?

Do insiders and institutionals believe in PROF or AVR?

Which has higher earnings and valuation, PROF or AVR?

Summary

How does Profound Medical compare to InMode?

Which has more risk & volatility, INMD or PROF?

Do analysts recommend INMD or PROF?

Which has higher valuation & earnings, INMD or PROF?

Do institutionals and insiders have more ownership in INMD or PROF?

Does the media prefer INMD or PROF?

Is INMD or PROF more profitable?

Summary

How does Profound Medical compare to Beta Bionics?

Which has more risk & volatility, BBNX or PROF?

Do insiders and institutionals believe in BBNX or PROF?

Does the media favor BBNX or PROF?

Is BBNX or PROF more profitable?

Which has stronger earnings & valuation, BBNX or PROF?

Do analysts recommend BBNX or PROF?

Summary

How does Profound Medical compare to SiBone?

Do institutionals and insiders hold more shares of SIBN or PROF?

Does the media prefer SIBN or PROF?

Is SIBN or PROF more profitable?

Which has stronger valuation and earnings, SIBN or PROF?

Which has more volatility & risk, SIBN or PROF?

Do analysts rate SIBN or PROF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROF vs. The Competition

Profound Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools